[1] BYRNE CD,TARGHER G. NAFLD:A multisystem disease[J]. J Hepatol,2015,62(S1):s47-s64.
|
[2] DUTOUR A,ABDESSELAM I,ANCEL P,et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes:A prospective randomized clinical trial using magnetic resonance imaging and spectroscopy[J]. Diabetes Obes Metab,2016,18(9):882-891.
|
[3] PANG BY,KUANG HY. Research progress of incretin-based therapies on nonalcoholic fatty liver disease[J]. China Med Herald,2018,15(6):28-30,34.(in Chinese)庞宝莹,匡洪宇.肠促胰素类药物治疗非酒精性脂肪性肝病研究进展[J].中国医药导报,2018,15(6):28-30,34.
|
[4] GAO H,ZENG Z,ZHANG H. The glucagon-like peptide-1analogue liraglutide inhibits oxidative stress and inflammatory response in the liver of rats with diet-induced non-alcoholic fatty liver disease[J]. Biol Pharm Bull,2015,38(5):694-702.
|
[5] YANG M,FUKUI H,EDA H,et al. Involvement of gut microbiota in association between GLP-1/GLP-1 receptor expression and gastrointestinal motility[J]. Am J Physiol Gastrointest Liver Physiol,2017,312(4):g367-g373.
|
[6] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版)[J].临床肝胆病杂志,2018,34(5):947-957.
|
[7] BOURSIER J,DIEHL AM. Implication of gut microbiota in nonalcoholic fatty liver disease[J]. PLo S Pathog,2015,11(1):e1004559.
|
[8] SANJOY R,PRAVEEN S,GAIL C. The role of the gut microbiome in nonalcoholic fatty liver disease[J]. Med Sci(Basel),2018,6(2). pii:e47.
|
[9] BOURSIER J,MUELLER O,BARRET M,et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic functifunction of the gut microbiota[J]. Hepatology,2016,63(3):764-775.
|
[10] LE ROY T,LLOPIS M,LEPAGE P,et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice[J]. Gut,2013,62(12):1787-1794.
|
[11] ALISI A,BEDOGNI G,BAVIERA G,et al. Randomised clinical trial:The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis[J]. Aliment Pharmacol Ther,2014,39(11):1276-1285.
|
[12] WANG W,SHI LP,SHI L,et al. Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease[J]. Chin J Intern Med,2018,57(2):101-106.(in Chinese)王薇,史林平,石蕾,等.肠道益生菌辅助治疗非酒精性脂肪性肝病的临床研究[J].中华内科杂志,2018,57(2):101-106.
|
[13] RONVEAUX CC,TOMD,RAYBOULD HE. Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling[J]. J Nutr,2015,145(4):672-680.
|
[14] HOU HT,QIU YM,ZHANG J,et al. GLP-1 down-regulates mRNA expression of SOCS-3 and SREBP-1c in rats with nonalcoholic fatty liver disease[J]. Chin J Pathophysiology,2016,32(7):1312-1316.(in Chinese)侯洪涛,裘艳梅,张建,等.GLP-1下调非酒精性脂肪肝大鼠SOCS-3和SREBP-1c的表达[J].中国病理生理杂志,2016,32(7):1312-1316.
|
[15] LIN CM,LIN WH,ZHOU R,et al. The research progresses on GLP-1 related signal pathways in alleviating non-alcoholic fatty liver disease[J]. Int J Endocrinol Metab,2018,38(3):179-182.(in Chinese)林楚曼,林伟浩,周蕊,等.GLP-1缓解非酒精性脂肪性肝病相关信号通路的研究进展[J].国际内分泌代谢杂志,2018,38(3):179-182.
|
[16] YAMANE S,INAGAKI N. Regulation of glucagon-like peptide-1 sensitivity by gut microbiota dysbiosis[J]. J Diabetes Investig,2018,9(2):262-264.
|